Sickle Cell Anemia Testing and Screening Market Size, Share and Growth Outlook 2026: By Test Type, By Age Group, By Sector Type, Companies to 2034
The global Sickle Cell Anemia Testing and Screening Market size is forecast to increase from $607.37 Million in 2026 to $1467.69 Million in 2034 at a CAGR of 11.66% between 2026 and 2034.
The Sickle Cell Anemia Testing and Screening market report provides detailed analysis and outlook of Sickle Cell Anemia Testing and Screening segments including By Test Type (Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests (POCT), Others), By Age Group (Newborn Screening, Adult Screening, Other Age Groups), By Sector Type (Government Labs, Private Labs, Corporate Labs, Public-Private Partnerships) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Sickle Cell Anemia Testing and Screening Industry Overview
Genomic Diagnostics, Point-of-Care Screening, and Precision Hematology Are Transforming the Sickle Cell Anemia Testing and Screening Industry
The sickle cell anemia testing and screening industry is undergoing significant transformation driven by advances in genomic diagnostics, decentralized screening technologies, and precision medicine approaches. Increasing global awareness of inherited hemoglobin disorders, expanding newborn and carrier screening programs, and the emergence of curative gene therapies are accelerating demand for more accurate and accessible diagnostic solutions. Healthcare systems and diagnostic manufacturers are increasingly focusing on integrated testing platforms that support early detection, carrier identification, therapeutic selection, and long-term disease management across diverse healthcare settings.
Next-Generation Sequencing Is Reshaping Hemoglobin Disorder Diagnostics
The growing complexity of inherited blood disorder management is driving adoption of high-resolution molecular diagnostic technologies capable of delivering comprehensive genetic characterization. Diagnostic developers are increasingly consolidating multiple testing workflows into single, regulatory-compliant platforms to improve clinical efficiency and diagnostic precision. This trend is exemplified by the launch of Devyser Thalassemia v2, the first European IVDR-compliant next-generation sequencing assay designed for the simultaneous genetic analysis of thalassemia and sickle cell disease. The introduction of integrated genomic testing platforms reflects the industry's broader transition toward precision diagnostics and personalized clinical decision-making in hemoglobinopathies.
Rapid Point-of-Care Testing Is Expanding Access to Early Screening
Access to rapid, affordable screening technologies remains a critical priority in regions with high disease prevalence and limited laboratory infrastructure. Manufacturers are increasingly developing simplified diagnostic formats that enable earlier identification of hemoglobin disorders in decentralized healthcare environments. This trend is demonstrated by Premier Medical Corporation's introduction of the First Response® Sickle Cell Detection Card Test, a qualitative diagnostic platform capable of identifying hemoglobin variants within minutes. The expansion of rapid screening technologies highlights the industry's commitment to improving accessibility and supporting large-scale public health screening initiatives.
Fundamental Genetic Discoveries Continue to Drive Diagnostic Innovation
Advances in the understanding of hemoglobin regulation and genetic disease mechanisms are reshaping both therapeutic development and diagnostic strategies. The recognition of Dr. Stuart Orkin with the Breakthrough Prize in Life Sciences for identifying BCL11A as a master regulator of fetal hemoglobin production underscores the profound impact of molecular genetics on sickle cell disease management. This foundational discovery directly enabled the development of gene-editing therapies such as Casgevy and continues to influence the development of novel diagnostic biomarkers, therapeutic monitoring tools, and targeted treatment strategies across the hemoglobin disorders landscape.
Sickle Cell Anemia Testing and Screening Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Sickle Cell Anemia Testing and Screening market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Bio-Rad Laboratories, Inc., Revvity, Inc. , Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Trinity Biotech plc, Streck, Inc., Hemex Health, Inc., Hemanext Inc.. The Sickle Cell Anemia Testing and Screening market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Sickle Cell Anemia Testing and Screening industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Sickle Cell Anemia Testing and Screening industry include- Bio-Rad Laboratories, Inc., Revvity, Inc. , Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Trinity Biotech plc, Streck, Inc., Hemex Health, Inc., Hemanext Inc.. The Sickle Cell Anemia Testing and Screening market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Sickle Cell Anemia Testing and Screening Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Sickle Cell Anemia Testing and Screening market remains one of the strongest-performing segments in the country.
The US Sickle Cell Anemia Testing and Screening Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Sickle Cell Anemia Testing and Screening market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Sickle Cell Anemia Testing and Screening industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Sickle Cell Anemia Testing and Screening markets
Canada's strong Sickle Cell Anemia Testing and Screening sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Sickle Cell Anemia Testing and Screening market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Sickle Cell Anemia Testing and Screening Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Sickle Cell Anemia Testing and Screening market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Sickle Cell Anemia Testing and Screening population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Sickle Cell Anemia Testing and Screening industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Sickle Cell Anemia Testing and Screening market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Sickle Cell Anemia Testing and Screening sales through 2034
France Sickle Cell Anemia Testing and Screening companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Sickle Cell Anemia Testing and Screening Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Sickle Cell Anemia Testing and Screening distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Sickle Cell Anemia Testing and Screening Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Sickle Cell Anemia Testing and Screening market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Sickle Cell Anemia Testing and Screening industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Sickle Cell Anemia Testing and Screening industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Sickle Cell Anemia Testing and Screening Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Sickle Cell Anemia Testing and Screening market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Sickle Cell Anemia Testing and Screening market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Sickle Cell Anemia Testing and Screening Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Sickle Cell Anemia Testing and Screening Market Segmentation
By Test Type
Hemoglobin Electrophoresis
High-Performance Liquid Chromatography (HPLC)
Point-of-Care Tests (POCT)
Others
By Age Group
Newborn Screening
Adult Screening
Other Age Groups
By Sector Type
Government Labs
Private Labs
Corporate Labs
Public-Private Partnerships
Leading Companies in Sickle Cell Anemia Testing and Screening Industry (2026)
Bio-Rad Laboratories, Inc.
Revvity, Inc.
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Trinity Biotech plc
Streck, Inc.
Hemex Health, Inc.
Hemanext Inc.
Countries Included
The Sickle Cell Anemia Testing and Screening market report provides detailed analysis and outlook of Sickle Cell Anemia Testing and Screening segments including By Test Type (Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests (POCT), Others), By Age Group (Newborn Screening, Adult Screening, Other Age Groups), By Sector Type (Government Labs, Private Labs, Corporate Labs, Public-Private Partnerships) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Sickle Cell Anemia Testing and Screening Industry Overview
Genomic Diagnostics, Point-of-Care Screening, and Precision Hematology Are Transforming the Sickle Cell Anemia Testing and Screening Industry
The sickle cell anemia testing and screening industry is undergoing significant transformation driven by advances in genomic diagnostics, decentralized screening technologies, and precision medicine approaches. Increasing global awareness of inherited hemoglobin disorders, expanding newborn and carrier screening programs, and the emergence of curative gene therapies are accelerating demand for more accurate and accessible diagnostic solutions. Healthcare systems and diagnostic manufacturers are increasingly focusing on integrated testing platforms that support early detection, carrier identification, therapeutic selection, and long-term disease management across diverse healthcare settings.
Next-Generation Sequencing Is Reshaping Hemoglobin Disorder Diagnostics
The growing complexity of inherited blood disorder management is driving adoption of high-resolution molecular diagnostic technologies capable of delivering comprehensive genetic characterization. Diagnostic developers are increasingly consolidating multiple testing workflows into single, regulatory-compliant platforms to improve clinical efficiency and diagnostic precision. This trend is exemplified by the launch of Devyser Thalassemia v2, the first European IVDR-compliant next-generation sequencing assay designed for the simultaneous genetic analysis of thalassemia and sickle cell disease. The introduction of integrated genomic testing platforms reflects the industry's broader transition toward precision diagnostics and personalized clinical decision-making in hemoglobinopathies.
Rapid Point-of-Care Testing Is Expanding Access to Early Screening
Access to rapid, affordable screening technologies remains a critical priority in regions with high disease prevalence and limited laboratory infrastructure. Manufacturers are increasingly developing simplified diagnostic formats that enable earlier identification of hemoglobin disorders in decentralized healthcare environments. This trend is demonstrated by Premier Medical Corporation's introduction of the First Response® Sickle Cell Detection Card Test, a qualitative diagnostic platform capable of identifying hemoglobin variants within minutes. The expansion of rapid screening technologies highlights the industry's commitment to improving accessibility and supporting large-scale public health screening initiatives.
Fundamental Genetic Discoveries Continue to Drive Diagnostic Innovation
Advances in the understanding of hemoglobin regulation and genetic disease mechanisms are reshaping both therapeutic development and diagnostic strategies. The recognition of Dr. Stuart Orkin with the Breakthrough Prize in Life Sciences for identifying BCL11A as a master regulator of fetal hemoglobin production underscores the profound impact of molecular genetics on sickle cell disease management. This foundational discovery directly enabled the development of gene-editing therapies such as Casgevy and continues to influence the development of novel diagnostic biomarkers, therapeutic monitoring tools, and targeted treatment strategies across the hemoglobin disorders landscape.
Sickle Cell Anemia Testing and Screening Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Sickle Cell Anemia Testing and Screening market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Bio-Rad Laboratories, Inc., Revvity, Inc. , Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Trinity Biotech plc, Streck, Inc., Hemex Health, Inc., Hemanext Inc.. The Sickle Cell Anemia Testing and Screening market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Sickle Cell Anemia Testing and Screening industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Sickle Cell Anemia Testing and Screening Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Sickle Cell Anemia Testing and Screening companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Sickle Cell Anemia Testing and Screening markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Sickle Cell Anemia Testing and Screening industry include- Bio-Rad Laboratories, Inc., Revvity, Inc. , Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Trinity Biotech plc, Streck, Inc., Hemex Health, Inc., Hemanext Inc.. The Sickle Cell Anemia Testing and Screening market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Sickle Cell Anemia Testing and Screening Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Sickle Cell Anemia Testing and Screening market remains one of the strongest-performing segments in the country.
The US Sickle Cell Anemia Testing and Screening Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Sickle Cell Anemia Testing and Screening market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Sickle Cell Anemia Testing and Screening industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Sickle Cell Anemia Testing and Screening markets
Canada's strong Sickle Cell Anemia Testing and Screening sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Sickle Cell Anemia Testing and Screening market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Sickle Cell Anemia Testing and Screening Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Sickle Cell Anemia Testing and Screening market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Sickle Cell Anemia Testing and Screening population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Sickle Cell Anemia Testing and Screening industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Sickle Cell Anemia Testing and Screening market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Sickle Cell Anemia Testing and Screening sales through 2034
France Sickle Cell Anemia Testing and Screening companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Sickle Cell Anemia Testing and Screening Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Sickle Cell Anemia Testing and Screening distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Sickle Cell Anemia Testing and Screening Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Sickle Cell Anemia Testing and Screening market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Sickle Cell Anemia Testing and Screening industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Sickle Cell Anemia Testing and Screening industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Sickle Cell Anemia Testing and Screening Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Sickle Cell Anemia Testing and Screening market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Sickle Cell Anemia Testing and Screening market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Sickle Cell Anemia Testing and Screening Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Sickle Cell Anemia Testing and Screening Market Segmentation
By Test Type
Hemoglobin Electrophoresis
High-Performance Liquid Chromatography (HPLC)
Point-of-Care Tests (POCT)
Others
By Age Group
Newborn Screening
Adult Screening
Other Age Groups
By Sector Type
Government Labs
Private Labs
Corporate Labs
Public-Private Partnerships
Leading Companies in Sickle Cell Anemia Testing and Screening Industry (2026)
Bio-Rad Laboratories, Inc.
Revvity, Inc.
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Trinity Biotech plc
Streck, Inc.
Hemex Health, Inc.
Hemanext Inc.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Sickle Cell Anemia Testing and Screening Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Sickle Cell Anemia Testing and Screening Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SICKLE CELL ANEMIA TESTING AND SCREENING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Sickle Cell Anemia Testing and Screening Markets in 2026
3.2. Global Historic and Forecast Sickle Cell Anemia Testing and Screening Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Sickle Cell Anemia Testing and Screening Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Sickle Cell Anemia Testing and Screening Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Sickle Cell Anemia Testing and Screening Value Chain
CHAPTER 4- SICKLE CELL ANEMIA TESTING AND SCREENING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Sickle Cell Anemia Testing and Screening Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SICKLE CELL ANEMIA TESTING AND SCREENING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Test Type
Hemoglobin Electrophoresis
High-Performance Liquid Chromatography (HPLC)
Point-of-Care Tests (POCT)
Others
By Age Group
Newborn Screening
Adult Screening
Other Age Groups
By Sector Type
Government Labs
Private Labs
Corporate Labs
Public-Private Partnerships
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Sickle Cell Anemia Testing and Screening Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
7.5. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
7.6. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
7.7. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Sickle Cell Anemia Testing and Screening Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Sickle Cell Anemia Testing and Screening Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Sickle Cell Anemia Testing and Screening Companies
CHAPTER 8- EUROPE SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Sickle Cell Anemia Testing and Screening Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
8.5. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
8.6. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
8.7. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Sickle Cell Anemia Testing and Screening Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Sickle Cell Anemia Testing and Screening Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Sickle Cell Anemia Testing and Screening Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Sickle Cell Anemia Testing and Screening Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Sickle Cell Anemia Testing and Screening Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Sickle Cell Anemia Testing and Screening Companies
CHAPTER 9- ASIA PACIFIC SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Sickle Cell Anemia Testing and Screening Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
9.6. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
9.7. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Sickle Cell Anemia Testing and Screening Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Sickle Cell Anemia Testing and Screening Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Sickle Cell Anemia Testing and Screening Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Sickle Cell Anemia Testing and Screening Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Sickle Cell Anemia Testing and Screening Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Sickle Cell Anemia Testing and Screening Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Sickle Cell Anemia Testing and Screening Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
10.5. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
10.6. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
10.7. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Sickle Cell Anemia Testing and Screening Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Sickle Cell Anemia Testing and Screening Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Sickle Cell Anemia Testing and Screening Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
11.6. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
11.7. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Sickle Cell Anemia Testing and Screening Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Sickle Cell Anemia Testing and Screening Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Sickle Cell Anemia Testing and Screening Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Sickle Cell Anemia Testing and Screening Industry
Bio-Rad Laboratories, Inc.
Revvity, Inc.
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Trinity Biotech plc
Streck, Inc.
Hemex Health, Inc.
Hemanext Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Sickle Cell Anemia Testing and Screening Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Sickle Cell Anemia Testing and Screening Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SICKLE CELL ANEMIA TESTING AND SCREENING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Sickle Cell Anemia Testing and Screening Markets in 2026
3.2. Global Historic and Forecast Sickle Cell Anemia Testing and Screening Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Sickle Cell Anemia Testing and Screening Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Sickle Cell Anemia Testing and Screening Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Sickle Cell Anemia Testing and Screening Value Chain
CHAPTER 4- SICKLE CELL ANEMIA TESTING AND SCREENING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Sickle Cell Anemia Testing and Screening Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SICKLE CELL ANEMIA TESTING AND SCREENING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Test Type
Hemoglobin Electrophoresis
High-Performance Liquid Chromatography (HPLC)
Point-of-Care Tests (POCT)
Others
By Age Group
Newborn Screening
Adult Screening
Other Age Groups
By Sector Type
Government Labs
Private Labs
Corporate Labs
Public-Private Partnerships
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Sickle Cell Anemia Testing and Screening Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
7.5. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
7.6. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
7.7. North America Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Sickle Cell Anemia Testing and Screening Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Sickle Cell Anemia Testing and Screening Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Sickle Cell Anemia Testing and Screening Companies
CHAPTER 8- EUROPE SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Sickle Cell Anemia Testing and Screening Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
8.5. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
8.6. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
8.7. Europe Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Sickle Cell Anemia Testing and Screening Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Sickle Cell Anemia Testing and Screening Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Sickle Cell Anemia Testing and Screening Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Sickle Cell Anemia Testing and Screening Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Sickle Cell Anemia Testing and Screening Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Sickle Cell Anemia Testing and Screening Companies
CHAPTER 9- ASIA PACIFIC SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Sickle Cell Anemia Testing and Screening Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
9.6. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
9.7. Asia Pacific Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Sickle Cell Anemia Testing and Screening Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Sickle Cell Anemia Testing and Screening Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Sickle Cell Anemia Testing and Screening Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Sickle Cell Anemia Testing and Screening Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Sickle Cell Anemia Testing and Screening Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Sickle Cell Anemia Testing and Screening Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Sickle Cell Anemia Testing and Screening Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
10.5. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
10.6. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
10.7. South and Central America Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Sickle Cell Anemia Testing and Screening Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Sickle Cell Anemia Testing and Screening Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Sickle Cell Anemia Testing and Screening Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SICKLE CELL ANEMIA TESTING AND SCREENING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Type
11.6. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Application
11.7. Middle East and Africa Sickle Cell Anemia Testing and Screening Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Sickle Cell Anemia Testing and Screening Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Sickle Cell Anemia Testing and Screening Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Sickle Cell Anemia Testing and Screening Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Sickle Cell Anemia Testing and Screening Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Sickle Cell Anemia Testing and Screening Industry
Bio-Rad Laboratories, Inc.
Revvity, Inc.
Danaher Corporation (Beckman Coulter)
Thermo Fisher Scientific Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Trinity Biotech plc
Streck, Inc.
Hemex Health, Inc.
Hemanext Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
